Physician profile
Ramsha Shafiq
NPI 1891349965
$1,053.05
in general payments reported to CMS, 2019-2025
17 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $212 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.27 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $173.29 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $156.68 | 2024-2025 | Minimed 780g |
| Amgen INC. | $121.31 | 2025 | Evenity, Prolia |
| Dexcom, INC. | $105.67 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $75.33 | 2025 | |
| Abbott Laboratories | $74.17 | 2024-2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $51.55 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $45.85 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Kyowa Kirin, INC. | $44.62 | 2024-2025 | Crysvita |
| Lilly USA, LLC | $40.55 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $29.67 | 2025 | |
| Sequel Med Tech, LLC | $29.62 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $22.77 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $22.71 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $22.52 | 2025 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $18.47 | 2025 | Flector, Tirosint, Licart |
| Radius Health, INC. | $18.27 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsha Shafiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.